2cureX German subsidiary receives contribution for the development of IndiTreat® tests in immuno-oncology
2cureX AB’s German subsidiary 2cureX GmbH (“2cureX”) has received funding from the German Federal Ministry of Education and Research to develop an IndiTreat® test for individualizing immuno-oncological treatment.
2cureX has received a grant of 810,000 EUR from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) to adapt the IndiTreat® to individualized immuno-oncology treatment. The project is run in collaboration with the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Hamburg-Eppendorf, UKE). 2cureX is co-financing the project with 378,000 EUR. The project will run until February 2020.
Immuno-oncology has shown tremendous success in a number of solid cancers, and it is one of the fastest growing areas within the oncology area. However, immunotherapy is not a “single silver bullet” as presented by the ASCO (American Society of Clinical Oncology) expert, Michael Sabel*: “Immunotherapy may not be a single silver bullet, but we may need several therapies in combination or one after the other to maximize its efficacy. We also need to develop better pre-treatment tests to find which patients are most likely to benefit and avoid side effects in patients who are not likely to benefit.”
IndiTreat® is a test that uniquely matches the specific patient with and efficacious treatment consisting of an individually tailored combination of approved cancer drugs.
Jürgen Kupper, Managing Director of 2cureX GmbH says: With support from BMBF we have established a strong collaborative team between UKE and 2cureX. Last week this team successfully presented their initial findings to BMBF at a site-visit in our facility in Hamburg. We look forward to expanding the capabilities of IndiTreat® into immuno-oncology”.
Sedermera Fondkommission is the Certified Adviser of 2cureX.
For more information about 2cureX:
Ole Thastrup, CEO; Phone: +45 22 11 53 99;
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).